E. I. Tashina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. I. Tashina has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Yuriy Nikitich Belenkov
Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications - E. V. Privalova
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
5 shared publications - V. Yu. Kaplunova
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
5 shared publications - Gayane A. Shakaryants
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
3 shared publications - Vysokikh A.V.
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
3 shared publications - Alfiya Oskarovna Iusupova
IM. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
1 shared publication
Latest Publications
- 29 March 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2)
Impact of microRNA-21 on the development of clinical variations and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy
Aim. To evaluate the impact of microRNA-21 expression levels on the development of clinical variants and risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Material and methods. The study included 84 participants as follows: 42 patients (22 men and 20 women) with a confirmed diagnosis of HCM, and 42 patients without HCM, matched for sex and age (the control group). The mean age of the participants was 57,2±14,2 years. All participants underwent a comprehensive examination, including electrocardiography, echocardiography assessing hypertrophy and diastolic function parameters, Holter monitoring, and laboratory tests (including N-terminal probrain natriuretic peptide). For molecular biology analysis, circulating microRNA-21 levels in plasma were measured in all participants using real-time polymerase chain reaction. Results. MicroRNA-21 levels were significantly elevated in all patients with HCM compared to the control group (pConclusion. MicroRNA-21 is a sensitive biomarker of pathological myocardial remodeling in HCM but is not suitable for stratifying individual SCD risk. The increased risk of SCD in progressive cases is likely due to different substrate not directly reflected by this microRNA level. Risk stratification should remain comprehensive.
- 29 March 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2)
Impact of microRNA-21 on the development of clinical variations and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy
Aim. To evaluate the impact of microRNA-21 expression levels on the development of clinical variants and risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Material and methods. The study included 84 participants as follows: 42 patients (22 men and 20 women) with a confirmed diagnosis of HCM, and 42 patients without HCM, matched for sex and age (the control group). The mean age of the participants was 57,2±14,2 years. All participants underwent a comprehensive examination, including electrocardiography, echocardiography assessing hypertrophy and diastolic function parameters, Holter monitoring, and laboratory tests (including N-terminal probrain natriuretic peptide). For molecular biology analysis, circulating microRNA-21 levels in plasma were measured in all participants using real-time polymerase chain reaction. Results. MicroRNA-21 levels were significantly elevated in all patients with HCM compared to the control group (pConclusion. MicroRNA-21 is a sensitive biomarker of pathological myocardial remodeling in HCM but is not suitable for stratifying individual SCD risk. The increased risk of SCD in progressive cases is likely due to different substrate not directly reflected by this microRNA level. Risk stratification should remain comprehensive.
- Open Access
- 11 February 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (1) , 31-37
Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group
Aim : To evaluate the diagnostic significance of a microRNA panel (-21, -29a, -133a) in patients with hypertrophic cardiomyopathy (HCM) by comparing their expression levels to a group with moderate arterial hypertension (comparison group). Material and methods : A comparative study was conducted involving 80 individuals: 40 patients with confirmed HCM and 40 sex- and age-matched controls (22 men, 18 women, mean age 55.3±13.3 years). All participants underwent a comprehensive examination at the cardiology department, including electrocardiography (ECG), echocardiography with full assessment of intracardiac hemodynamic parameters, Holter ECG monitoring, and laboratory tests. For molecular biological analysis, plasma expression levels of circulating microRNAs (-21, -29a, -133a) were determined for all participants using real-time polymerase chain reaction. Results : Circulating microRNA levels differed significantly between patients with HCM and the comparison group. The analysis showed a significant increase in the microRNA-21 expression (4.07 v s . 2.03; p vs . 1.83; p vs . 6.34; p Conclusion : Increased expression of microRNA-21 and decreased expression of microRNA-29a are associated with myocardial fibrosis, while marked suppression of microRNA-133a reflects hypertrophic remodeling. These findings suggest that this microRNA panel holds promise as potential auxiliary markers for HCM, though clinical significance requires validation in larger, prospective studies.
- 11 February 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (1) , 31-37
Open AccessIntegrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group
Aim : To evaluate the diagnostic significance of a microRNA panel (-21, -29a, -133a) in patients with hypertrophic cardiomyopathy (HCM) by comparing their expression levels to a group with moderate arterial hypertension (comparison group). Material and methods : A comparative study was conducted involving 80 individuals: 40 patients with confirmed HCM and 40 sex- and age-matched controls (22 men, 18 women, mean age 55.3±13.3 years). All participants underwent a comprehensive examination at the cardiology department, including electrocardiography (ECG), echocardiography with full assessment of intracardiac hemodynamic parameters, Holter ECG monitoring, and laboratory tests. For molecular biological analysis, plasma expression levels of circulating microRNAs (-21, -29a, -133a) were determined for all participants using real-time polymerase chain reaction. Results : Circulating microRNA levels differed significantly between patients with HCM and the comparison group. The analysis showed a significant increase in the microRNA-21 expression (4.07 v s . 2.03; p vs . 1.83; p vs . 6.34; p Conclusion : Increased expression of microRNA-21 and decreased expression of microRNA-29a are associated with myocardial fibrosis, while marked suppression of microRNA-133a reflects hypertrophic remodeling. These findings suggest that this microRNA panel holds promise as potential auxiliary markers for HCM, though clinical significance requires validation in larger, prospective studies.
- 5 February 2026
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 16 (1)
Young Patient with Alport Syndrome and End-Stage Renal Disease. A Clinical Observation
Alport syndrome (AS) is a genetically determined disease caused by abnormalities in the genes encoding alpha-3/4/5 chains of type IV collagen. Collagen IV is the most important structural component of the glomerular basement membranes, retina and inner ear, therefore, genetic mutations in this disease lead to kidney damage, vision and hearing impairment. Depending on the type of mutation, the clinical features of AS vary from asymptomatic decrease to early development of end-stage renal disease (ESRD), hearing loss and blindness. At the same time, AS is one of the most common causes of familial proteinuria in the population. Historically, this disease was considered a pediatric disease and more common in males, although currently its prevalence among women is high. The female sex is associated with a milder course and late development of complications, including vision and hearing impairment and ESRD. According to J.P. Jais et al., ESRD is observed by the age of 45 in 12 % of patients with the x-linked variant of AS. Early onset of severe manifestations is quite rare, which leads to insufficient diagnosis of genetically determined kidney diseases, late genetic testing and initiation of treatment, including transplantation. Currently, the problem of detection, therapeutic and surgical treatment of AS remains a difficult issue to resolve.This article presents a clinical case of diagnosis and management of a young patient with the x-linked COL4A5 variant of AS, complicated by renal parenchymal hypertension and early progression to ESRD, which required renal replacement therapy (dialysis) and kidney transplantation. The subsequent 2.5-year follow-up showed a significant improvement in the condition of target organs against the background of timely treatment.
- 5 February 2026
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 16 (1)
Young Patient with Alport Syndrome and End-Stage Renal Disease. A Clinical Observation
Alport syndrome (AS) is a genetically determined disease caused by abnormalities in the genes encoding alpha-3/4/5 chains of type IV collagen. Collagen IV is the most important structural component of the glomerular basement membranes, retina and inner ear, therefore, genetic mutations in this disease lead to kidney damage, vision and hearing impairment. Depending on the type of mutation, the clinical features of AS vary from asymptomatic decrease to early development of end-stage renal disease (ESRD), hearing loss and blindness. At the same time, AS is one of the most common causes of familial proteinuria in the population. Historically, this disease was considered a pediatric disease and more common in males, although currently its prevalence among women is high. The female sex is associated with a milder course and late development of complications, including vision and hearing impairment and ESRD. According to J.P. Jais et al., ESRD is observed by the age of 45 in 12 % of patients with the x-linked variant of AS. Early onset of severe manifestations is quite rare, which leads to insufficient diagnosis of genetically determined kidney diseases, late genetic testing and initiation of treatment, including transplantation. Currently, the problem of detection, therapeutic and surgical treatment of AS remains a difficult issue to resolve.This article presents a clinical case of diagnosis and management of a young patient with the x-linked COL4A5 variant of AS, complicated by renal parenchymal hypertension and early progression to ESRD, which required renal replacement therapy (dialysis) and kidney transplantation. The subsequent 2.5-year follow-up showed a significant improvement in the condition of target organs against the background of timely treatment.
- Open Access
- 31 January 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 58-66
The Structure of Concomitant Pathology in Patients With Hypertrophic Cardiomyopathy in The Older Age Group. Review and Clinical Observations
Advances in modern drug and surgical treatment of patients with hypertrophic cardiomyopathy (HCM) have resulted in a significant increase in the life expectancy of these extremely severe patients. Therefore, in addition to the genetic markers, major neurohumoral systems and morpho-functional parameters of intracardiac hemodynamics, the course and prognosis of the disease are influenced by concomitant pathology. In infancy and early childhood, HCM is associated with tumors of chromaffin tissue of various localizations; however, the older the patient, the greater the likelihood of developing metabolic syndrome, secondary atherosclerosis and ischemic heart disease (IHD), and hypertension, which significantly complicates the verification of the HCM diagnosis. We have previously described cases of IHD secondary to HCM, which significantly affected the course and prognosis of both diseases. However, in old age, other comorbidities may also occur in addition to the diseases described above. Based on long-term observation of a large cohort of patients, this article analyzes a wide range of HCM combinations with pathology of other organs and systems, including malignant neoplasms, which makes significant adjustments to the treatment of both the underlying disease and cancer. The material is presented in the form of a brief review of literature on this topic and our own clinical observations and studies.
- 31 January 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 58-66
Open AccessThe Structure of Concomitant Pathology in Patients With Hypertrophic Cardiomyopathy in The Older Age Group. Review and Clinical Observations
Advances in modern drug and surgical treatment of patients with hypertrophic cardiomyopathy (HCM) have resulted in a significant increase in the life expectancy of these extremely severe patients. Therefore, in addition to the genetic markers, major neurohumoral systems and morpho-functional parameters of intracardiac hemodynamics, the course and prognosis of the disease are influenced by concomitant pathology. In infancy and early childhood, HCM is associated with tumors of chromaffin tissue of various localizations; however, the older the patient, the greater the likelihood of developing metabolic syndrome, secondary atherosclerosis and ischemic heart disease (IHD), and hypertension, which significantly complicates the verification of the HCM diagnosis. We have previously described cases of IHD secondary to HCM, which significantly affected the course and prognosis of both diseases. However, in old age, other comorbidities may also occur in addition to the diseases described above. Based on long-term observation of a large cohort of patients, this article analyzes a wide range of HCM combinations with pathology of other organs and systems, including malignant neoplasms, which makes significant adjustments to the treatment of both the underlying disease and cancer. The material is presented in the form of a brief review of literature on this topic and our own clinical observations and studies.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
PROGNOSTIC ROLE OF NEUROHUMORAL AND EPIGENETIC MARKERS IN THE FORMATION OF PHENOTYPIC MANIFESTATIONS OF HYPERTROPHIC CARDIOMYOPATHY
At the present time, the problem of studying hypertrophic cardiomyopathy (HCM) remains relevant due to the severity of this disease and the high risk of sudden cardiac death in the population, in particular in young and working age population, which can often be the first and only manifestation of this pathology. Consequently, the search for additional methods of early diagnosis and the development of tools for predicting the course of the disease remain priority areas of research in cardiology. Modern fundamental and clinical studies conducted all over the world are mostly focused on the search for relevant and accessible biomarkers in clinical practice of a doctor, among which special attention is paid to neurohumoral and epigenetic markers, which can be closely related to the possible outcome, the variant of the course of HCM in a patient, as well as can correlate with certain morphometric parameters according to the instrumental methods of examination and clinical picture, which in turn will later serve as a basis for a patient's personalised approach. These studies offer significant prospects for a patient personalised approach. Our review of the current literature on this topic is devoted to the analysis of current trends in cardiology, in particular, in the possible diagnosis and prognostic role of the course of HCM on the basis of neurohumoral and epigenetic markers. Particular attention is paid to the evaluation of the role of miR-29a and TGF-β 1 in patients with different variants of the course of HCM.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
PROGNOSTIC ROLE OF NEUROHUMORAL AND EPIGENETIC MARKERS IN THE FORMATION OF PHENOTYPIC MANIFESTATIONS OF HYPERTROPHIC CARDIOMYOPATHY
At the present time, the problem of studying hypertrophic cardiomyopathy (HCM) remains relevant due to the severity of this disease and the high risk of sudden cardiac death in the population, in particular in young and working age population, which can often be the first and only manifestation of this pathology. Consequently, the search for additional methods of early diagnosis and the development of tools for predicting the course of the disease remain priority areas of research in cardiology. Modern fundamental and clinical studies conducted all over the world are mostly focused on the search for relevant and accessible biomarkers in clinical practice of a doctor, among which special attention is paid to neurohumoral and epigenetic markers, which can be closely related to the possible outcome, the variant of the course of HCM in a patient, as well as can correlate with certain morphometric parameters according to the instrumental methods of examination and clinical picture, which in turn will later serve as a basis for a patient's personalised approach. These studies offer significant prospects for a patient personalised approach. Our review of the current literature on this topic is devoted to the analysis of current trends in cardiology, in particular, in the possible diagnosis and prognostic role of the course of HCM on the basis of neurohumoral and epigenetic markers. Particular attention is paid to the evaluation of the role of miR-29a and TGF-β 1 in patients with different variants of the course of HCM.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
DEVELOPMENT OF A PERSONALIZED TECHNIQUE FOR EARLY DIAGNOSIS AND PREDICTION OF VARIANTS OF THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY BASED ON THE ANALYSIS OF MICRORNAS-21, 29A, 133A
For many years, cardiovascular diseases have occupied and continue to occupy leading positions due to mortality and disability of the adult working-age population. Hypertrophic cardiomyopathy (HCM) is the most common variant of cardiomyopathy, its prevalence among the general population worldwide is 0.2% (1 in 500 adults). The study of the disease has been taking place for quite a long time, the half-century history of studying the problem of HCMP reflects a significant evolution of knowledge in matters of etiology, pathogenesis, diagnosis, clinical course and prognosis, variants of the course of the disease, however, there are still no methods of early diagnosis that could be used as a possible screening of this condition in the early stages and forecasting its more severe course. New methods could make it possible to diagnose this condition at an early stage and predict a possible course of its course, thereby preventing such a formidable complication as sudden cardiac death (SCD). At the moment, there is a prediction model (HCM Risk-SCD) for the risk of SCD, based on the results of instrumental research methods and anamnesis data of a particular patient, but this model is not perfect enough, and therefore it is gaining great popularity and the search for various biomarkers continues based on well-known scientific achievements in the field of genomics and transcriptomics. Perhaps in the near future, the study of the levels of certain microRNAs, which have already proven their affinity for the degree of myocardial hypertrophy, will become a new milestone in the study of hypertrophic cardiomyopathy.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
DEVELOPMENT OF A PERSONALIZED TECHNIQUE FOR EARLY DIAGNOSIS AND PREDICTION OF VARIANTS OF THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY BASED ON THE ANALYSIS OF MICRORNAS-21, 29A, 133A
For many years, cardiovascular diseases have occupied and continue to occupy leading positions due to mortality and disability of the adult working-age population. Hypertrophic cardiomyopathy (HCM) is the most common variant of cardiomyopathy, its prevalence among the general population worldwide is 0.2% (1 in 500 adults). The study of the disease has been taking place for quite a long time, the half-century history of studying the problem of HCMP reflects a significant evolution of knowledge in matters of etiology, pathogenesis, diagnosis, clinical course and prognosis, variants of the course of the disease, however, there are still no methods of early diagnosis that could be used as a possible screening of this condition in the early stages and forecasting its more severe course. New methods could make it possible to diagnose this condition at an early stage and predict a possible course of its course, thereby preventing such a formidable complication as sudden cardiac death (SCD). At the moment, there is a prediction model (HCM Risk-SCD) for the risk of SCD, based on the results of instrumental research methods and anamnesis data of a particular patient, but this model is not perfect enough, and therefore it is gaining great popularity and the search for various biomarkers continues based on well-known scientific achievements in the field of genomics and transcriptomics. Perhaps in the near future, the study of the levels of certain microRNAs, which have already proven their affinity for the degree of myocardial hypertrophy, will become a new milestone in the study of hypertrophic cardiomyopathy.